Aromatase Inhibitor + Growth Hormone Can Optimize Height

Share this content:
Aromatase Inhibitor + Growth Hormone Can Optimize Height
Aromatase Inhibitor + Growth Hormone Can Optimize Height

FRIDAY, Jan. 27, 2017 (HealthDay News) -- Use of an aromatase inhibitor in combination with growth hormone seems effective for optimizing height in 11β-hydroxylase-deficient congenital adrenal hyperplasia (CAH), according to a case report published online Jan. 26 in Pediatrics.

Katherine Hawton, M.B.B.S., from the Bristol Royal Hospital for Children in the United Kingdom, and colleagues describe a 6-year-old patient with CAH who had been suboptimally treated and presented with precocious puberty, hypertension, tall stature, advanced bone age, and a predicted final height of 150 cm.

The researchers confirmed a diagnosis of 11β-hydroxylase deficiency in hormonal profiles and genetic analysis. In an attempt to optimize the patient's growth, he was started on growth hormone and a third-generation aromatase inhibitor, anastrozole, in addition to glucocorticoid replacement. The patient's growth rate improved significantly after initiation of treatment and his bone age advancement slowed. The patient reached a final height of 177.5 cm, which was 11.5 cm above his mid-parental height.

"This patient is only the second reported case of the use of an aromatase inhibitor in combination with growth hormone to optimize height in 11β-hydroxylase-deficient CAH," the authors write. "This novel treatment proved to be highly efficacious, with no adverse effects."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »